Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project
To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA. Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were assessed by questionnaire. To calculate the 10-year CV risk score ac...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2017-09, Vol.56 (9), p.1472-1478 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1478 |
|---|---|
| container_issue | 9 |
| container_start_page | 1472 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 56 |
| creator | van den Oever, Inge A M Heslinga, Maaike Griep, Ed N Griep-Wentink, Hanneke R M Schotsman, Rob Cambach, Walter Dijkmans, Ben A C Smulders, Yvo M Lems, Willem F Boers, Maarten Voskuyl, Alexandre E Peters, Mike J L van Schaardenburg, Dirkjan Nurmohamed, Micheal T |
| description | To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA.
Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were assessed by questionnaire. To calculate the 10-year CV risk score according to the Dutch CV risk management guideline, systolic blood pressure was measured and cholesterol levels were determined from fasting blood samples. Patients were categorized into four groups: indication for treatment but not treated; inadequately treated, so not meeting goals (systolic blood pressure ⩽140 mmHg and/or low-density lipoprotein ⩽2.5 mmol/l); adequately treated; or no treatment necessary.
A total of 720 consecutive RA patients were included, 375 from Reade and 345 from the Antonius Hospital. The mean age of patients was 59 years (s.d. 12) and 73% were female. Seventeen per cent of the patients had a low 10-year CV risk ( |
| doi_str_mv | 10.1093/rheumatology/kew497 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1869071672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1869071672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-b2db63e4c6b0f6ed9ffef1e64c5851b89b4d6b824b6362c3151e287c4eb66ab23</originalsourceid><addsrcrecordid>eNpdkVtLxDAQhYMo3n-BIHn0ZTW3pq1vsniDFUH0uSTp1I2mzZqkyv4hf6ddd70-zcCccz6Yg9ABJceUlPwkTKFvVfLOP85PnuFNlPka2qZCshHhnK1_70xsoZ0YnwghGeXFJtpiBS3LnIlt9D5Wobb-VUXTOxVwsPEZt6pTj9BCl7Dt8BfH1liFNA022YhnKtnhHnFM1jkce-1nybbKneI0BXzdztxnwCDzHfYN_se5W3Bu_nDufjhnP5zgn8CkPbTRKBdhfzV30cPF-f34ajS5vbwen01GhmckjTSrteQgjNSkkVCXTQMNBSlMVmRUF6UWtdQFE4NKMsNpRoEVuRGgpVSa8V10tMwduC89xFS1NhpwTnXg-1jRQpYkpzJfSPlSaoKPMUBTzcLwgDCvKKkWBVW_C6qWBQ2uwxWg1y3U356vRvgHUmuXgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1869071672</pqid></control><display><type>article</type><title>Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>van den Oever, Inge A M ; Heslinga, Maaike ; Griep, Ed N ; Griep-Wentink, Hanneke R M ; Schotsman, Rob ; Cambach, Walter ; Dijkmans, Ben A C ; Smulders, Yvo M ; Lems, Willem F ; Boers, Maarten ; Voskuyl, Alexandre E ; Peters, Mike J L ; van Schaardenburg, Dirkjan ; Nurmohamed, Micheal T</creator><creatorcontrib>van den Oever, Inge A M ; Heslinga, Maaike ; Griep, Ed N ; Griep-Wentink, Hanneke R M ; Schotsman, Rob ; Cambach, Walter ; Dijkmans, Ben A C ; Smulders, Yvo M ; Lems, Willem F ; Boers, Maarten ; Voskuyl, Alexandre E ; Peters, Mike J L ; van Schaardenburg, Dirkjan ; Nurmohamed, Micheal T</creatorcontrib><description>To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA.
Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were assessed by questionnaire. To calculate the 10-year CV risk score according to the Dutch CV risk management guideline, systolic blood pressure was measured and cholesterol levels were determined from fasting blood samples. Patients were categorized into four groups: indication for treatment but not treated; inadequately treated, so not meeting goals (systolic blood pressure ⩽140 mmHg and/or low-density lipoprotein ⩽2.5 mmol/l); adequately treated; or no treatment necessary.
A total of 720 consecutive RA patients were included, 375 from Reade and 345 from the Antonius Hospital. The mean age of patients was 59 years (s.d. 12) and 73% were female. Seventeen per cent of the patients had a low 10-year CV risk (<10%), 21% had an intermediate risk (10-19%), 53% a high risk (⩾20%) and 9% had CVD. In total, 69% had an indication for preventive treatment (cholesterol-lowering or antihypertensive drugs). Of those, 42% received inadequate treatment and 40% received no treatment at all.
Optimal CV risk management remains a major challenge and better awareness and management are urgently needed to reduce the high risk of CVD in the RA population.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kew497</identifier><identifier>PMID: 28199724</identifier><language>eng</language><publisher>England</publisher><subject>Aged ; Antihypertensive Agents - therapeutic use ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - epidemiology ; Arthritis, Rheumatoid - physiopathology ; Blood Pressure - physiology ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - physiopathology ; Cardiovascular Diseases - prevention & control ; Cholesterol - blood ; Cross-Sectional Studies ; Drug Therapy, Combination ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Male ; Middle Aged ; Netherlands - epidemiology ; Prevalence ; Risk Assessment - methods ; Risk Factors ; Risk Management - methods ; Risk Management - standards</subject><ispartof>Rheumatology (Oxford, England), 2017-09, Vol.56 (9), p.1472-1478</ispartof><rights>The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c350t-b2db63e4c6b0f6ed9ffef1e64c5851b89b4d6b824b6362c3151e287c4eb66ab23</citedby><cites>FETCH-LOGICAL-c350t-b2db63e4c6b0f6ed9ffef1e64c5851b89b4d6b824b6362c3151e287c4eb66ab23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28199724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van den Oever, Inge A M</creatorcontrib><creatorcontrib>Heslinga, Maaike</creatorcontrib><creatorcontrib>Griep, Ed N</creatorcontrib><creatorcontrib>Griep-Wentink, Hanneke R M</creatorcontrib><creatorcontrib>Schotsman, Rob</creatorcontrib><creatorcontrib>Cambach, Walter</creatorcontrib><creatorcontrib>Dijkmans, Ben A C</creatorcontrib><creatorcontrib>Smulders, Yvo M</creatorcontrib><creatorcontrib>Lems, Willem F</creatorcontrib><creatorcontrib>Boers, Maarten</creatorcontrib><creatorcontrib>Voskuyl, Alexandre E</creatorcontrib><creatorcontrib>Peters, Mike J L</creatorcontrib><creatorcontrib>van Schaardenburg, Dirkjan</creatorcontrib><creatorcontrib>Nurmohamed, Micheal T</creatorcontrib><title>Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA.
Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were assessed by questionnaire. To calculate the 10-year CV risk score according to the Dutch CV risk management guideline, systolic blood pressure was measured and cholesterol levels were determined from fasting blood samples. Patients were categorized into four groups: indication for treatment but not treated; inadequately treated, so not meeting goals (systolic blood pressure ⩽140 mmHg and/or low-density lipoprotein ⩽2.5 mmol/l); adequately treated; or no treatment necessary.
A total of 720 consecutive RA patients were included, 375 from Reade and 345 from the Antonius Hospital. The mean age of patients was 59 years (s.d. 12) and 73% were female. Seventeen per cent of the patients had a low 10-year CV risk (<10%), 21% had an intermediate risk (10-19%), 53% a high risk (⩾20%) and 9% had CVD. In total, 69% had an indication for preventive treatment (cholesterol-lowering or antihypertensive drugs). Of those, 42% received inadequate treatment and 40% received no treatment at all.
Optimal CV risk management remains a major challenge and better awareness and management are urgently needed to reduce the high risk of CVD in the RA population.</description><subject>Aged</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - epidemiology</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Blood Pressure - physiology</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - physiopathology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cholesterol - blood</subject><subject>Cross-Sectional Studies</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Netherlands - epidemiology</subject><subject>Prevalence</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Risk Management - methods</subject><subject>Risk Management - standards</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkVtLxDAQhYMo3n-BIHn0ZTW3pq1vsniDFUH0uSTp1I2mzZqkyv4hf6ddd70-zcCccz6Yg9ABJceUlPwkTKFvVfLOP85PnuFNlPka2qZCshHhnK1_70xsoZ0YnwghGeXFJtpiBS3LnIlt9D5Wobb-VUXTOxVwsPEZt6pTj9BCl7Dt8BfH1liFNA022YhnKtnhHnFM1jkce-1nybbKneI0BXzdztxnwCDzHfYN_se5W3Bu_nDufjhnP5zgn8CkPbTRKBdhfzV30cPF-f34ajS5vbwen01GhmckjTSrteQgjNSkkVCXTQMNBSlMVmRUF6UWtdQFE4NKMsNpRoEVuRGgpVSa8V10tMwduC89xFS1NhpwTnXg-1jRQpYkpzJfSPlSaoKPMUBTzcLwgDCvKKkWBVW_C6qWBQ2uwxWg1y3U356vRvgHUmuXgw</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>van den Oever, Inge A M</creator><creator>Heslinga, Maaike</creator><creator>Griep, Ed N</creator><creator>Griep-Wentink, Hanneke R M</creator><creator>Schotsman, Rob</creator><creator>Cambach, Walter</creator><creator>Dijkmans, Ben A C</creator><creator>Smulders, Yvo M</creator><creator>Lems, Willem F</creator><creator>Boers, Maarten</creator><creator>Voskuyl, Alexandre E</creator><creator>Peters, Mike J L</creator><creator>van Schaardenburg, Dirkjan</creator><creator>Nurmohamed, Micheal T</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project</title><author>van den Oever, Inge A M ; Heslinga, Maaike ; Griep, Ed N ; Griep-Wentink, Hanneke R M ; Schotsman, Rob ; Cambach, Walter ; Dijkmans, Ben A C ; Smulders, Yvo M ; Lems, Willem F ; Boers, Maarten ; Voskuyl, Alexandre E ; Peters, Mike J L ; van Schaardenburg, Dirkjan ; Nurmohamed, Micheal T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-b2db63e4c6b0f6ed9ffef1e64c5851b89b4d6b824b6362c3151e287c4eb66ab23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - epidemiology</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Blood Pressure - physiology</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - physiopathology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cholesterol - blood</topic><topic>Cross-Sectional Studies</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Netherlands - epidemiology</topic><topic>Prevalence</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Risk Management - methods</topic><topic>Risk Management - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van den Oever, Inge A M</creatorcontrib><creatorcontrib>Heslinga, Maaike</creatorcontrib><creatorcontrib>Griep, Ed N</creatorcontrib><creatorcontrib>Griep-Wentink, Hanneke R M</creatorcontrib><creatorcontrib>Schotsman, Rob</creatorcontrib><creatorcontrib>Cambach, Walter</creatorcontrib><creatorcontrib>Dijkmans, Ben A C</creatorcontrib><creatorcontrib>Smulders, Yvo M</creatorcontrib><creatorcontrib>Lems, Willem F</creatorcontrib><creatorcontrib>Boers, Maarten</creatorcontrib><creatorcontrib>Voskuyl, Alexandre E</creatorcontrib><creatorcontrib>Peters, Mike J L</creatorcontrib><creatorcontrib>van Schaardenburg, Dirkjan</creatorcontrib><creatorcontrib>Nurmohamed, Micheal T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van den Oever, Inge A M</au><au>Heslinga, Maaike</au><au>Griep, Ed N</au><au>Griep-Wentink, Hanneke R M</au><au>Schotsman, Rob</au><au>Cambach, Walter</au><au>Dijkmans, Ben A C</au><au>Smulders, Yvo M</au><au>Lems, Willem F</au><au>Boers, Maarten</au><au>Voskuyl, Alexandre E</au><au>Peters, Mike J L</au><au>van Schaardenburg, Dirkjan</au><au>Nurmohamed, Micheal T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>56</volume><issue>9</issue><spage>1472</spage><epage>1478</epage><pages>1472-1478</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>To assess the 10-year cardiovascular (CV) risk score and to identify treatment and undertreatment of CV risk factors in patients with established RA.
Demographics, CV risk factors and prevalence of cardiovascular disease (CVD) were assessed by questionnaire. To calculate the 10-year CV risk score according to the Dutch CV risk management guideline, systolic blood pressure was measured and cholesterol levels were determined from fasting blood samples. Patients were categorized into four groups: indication for treatment but not treated; inadequately treated, so not meeting goals (systolic blood pressure ⩽140 mmHg and/or low-density lipoprotein ⩽2.5 mmol/l); adequately treated; or no treatment necessary.
A total of 720 consecutive RA patients were included, 375 from Reade and 345 from the Antonius Hospital. The mean age of patients was 59 years (s.d. 12) and 73% were female. Seventeen per cent of the patients had a low 10-year CV risk (<10%), 21% had an intermediate risk (10-19%), 53% a high risk (⩾20%) and 9% had CVD. In total, 69% had an indication for preventive treatment (cholesterol-lowering or antihypertensive drugs). Of those, 42% received inadequate treatment and 40% received no treatment at all.
Optimal CV risk management remains a major challenge and better awareness and management are urgently needed to reduce the high risk of CVD in the RA population.</abstract><cop>England</cop><pmid>28199724</pmid><doi>10.1093/rheumatology/kew497</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2017-09, Vol.56 (9), p.1472-1478 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1869071672 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Aged Antihypertensive Agents - therapeutic use Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - epidemiology Arthritis, Rheumatoid - physiopathology Blood Pressure - physiology Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cardiovascular Diseases - physiopathology Cardiovascular Diseases - prevention & control Cholesterol - blood Cross-Sectional Studies Drug Therapy, Combination Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Middle Aged Netherlands - epidemiology Prevalence Risk Assessment - methods Risk Factors Risk Management - methods Risk Management - standards |
| title | Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A38%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20risk%20management%20in%20rheumatoid%20arthritis%20patients%20still%20suboptimal:%20the%20Implementation%20of%20Cardiovascular%20Risk%20Management%20in%20Rheumatoid%20Arthritis%20project&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=van%20den%20Oever,%20Inge%20A%20M&rft.date=2017-09-01&rft.volume=56&rft.issue=9&rft.spage=1472&rft.epage=1478&rft.pages=1472-1478&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kew497&rft_dat=%3Cproquest_cross%3E1869071672%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1869071672&rft_id=info:pmid/28199724&rfr_iscdi=true |